Happy Hanukkah to all who celebrate! May light and joy fill your homes

The U.S. markets are open! 🛎️👏Late-stage clinical biopharmaceutical company CG Oncology, Inc. rings in its listing on Nasdaq Exchange!

🗓️ Begin your #AUA24 experience tomorrow, May 3rd with @CGOncology! Hear Mark Tyson present BOND-003: Phase 3 results of cretostimogene at 10:23 am CDT in the Stars at Night Ballroom, and afterwards meet our Medical Team at booth #100. Come join us! 🤝 auanet.org/AUA2024

Please join us tomorrow, May 3rd, in paradigm shifting practice changing trials session at #AUA24. We will be presenting pivotal results of BOND-003, a phase 3 study of cretostimogene grenadenorepvec for BCGu #BladderCancer, at 10:23 am CDT in the Stars at Night Ballroom.

Highly recommend this. Provides context to and vision behind P2 and other innovative changes at AUA this year

📄 @CGOncology is excited to share updated BOND-003 study results for BCG-unresponsive #NMIBC presented by Mark Tyson at #AUA24. Thank you to the patients & investigators for advancing this research. Join our IR webcast today at 4:30pm ET for details: ir.cgoncology.com/news-releases/…

Pivotal results from #BOND-003: a phase 3, single-arm Study of Intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive #NMIBC. Presentation by Mark Tyson Mayo Clinic. #AUA24 coverage by Zach Klaassen > bit.ly/44HXzs5 Amer. Urol. Assn.

📄Phase 2 CORE-001 Final Results: Cretostimogene in combination w/pembrolizumab for BCG-unresponsive HR-#NMIBC showed a 54% (19/35) complete response (CR) rate at 24 months. Poster will be presented at #ASCO24 Roger Li @GarySteinbergMD @TBivala1 bit.ly/3QZhf4T

Unveiling our CORE-001 trial results tomorrow at #ASCO24 for BCG-unresponsive HR-#NMIBC! Discover insights into safety, efficacy, and patient-reported outcomes. See how we aim to improve the entire spectrum of #bladdercancer care. Roger Li @garysteinbergMD @TBivala1

Today at #ASCO24: In a phase 2 trial evaluating intravesical delivery of an oncolytic adenovirus + anti-PD-1 in patients with BCG unresponsive, non-muscle invasive #BladderCancer, the complete response rate at 12 months was 57.1% Roger Li doi.org/10.1038/s41591…

👏 We're thrilled to share positive results from our Phase 2 CORE-001 trial on #NationalCancerSurvivorsDay at #ASCO24! Thank you Roger Li for presenting our poster, and to all our dedicated patients & collaborators. See details: ASCO Poster Board #296 (Abstract #4601)

#ASCO24 CORE-001: Ph 2, single arm study of Creto + Pembro in BCG-UR, NMIBC w/ CIS Roger Li UroToday.com CG Oncology, Inc. ⚡️n=35 ⚡️CR rate 12 mo: 57.1% ⚡️CR rate 24 mo: 54.3% ⚡️CR rate any time: 82.9% ⚡️95.1% of CRs @ 12 mo remain in CR @ 24 mo ⚡️12 mo landmark RFS: 77.3% ⚡️24 mo

Final results of #CORE001 trial out now Nature Medicine (1/14) 35 pts with BCG-UR CIS treated w/ Creto + pembro 👉12mo CR (per RBB) = 57.1% (ITT) 👉24mo CR = 54% *(Auth Corr) 👉No patient progressed to MIBC 👉No synergistic toxicity Gary Steinberg nature.com/articles/s4159…

urotoday.com/video-lectures… via UroToday.com

An expanded access program for cretostimogene grenadenorepvec has been initiated for patients in the US with BCG-unresponsive NMIBC. #blcsm #urology urologytimes.com/view/cretostim…

#PIVOT-006: A new chapter in #BladderCancer treatment. Mark Tyson Mayo Clinic joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss CG Oncology, Inc.'s advancements in bladder cancer treatment, focusing on the PIVOT study and other trials. #WatchNow on UroToday > bit.ly/3weGl8m

Moffitt Cancer Center Beyond thrilled to present the data from #CORE2, using neoadj IVe Creto + Nivo in cis-ineligible MIBC #SITC24 Nature Medicine🚨🚨🚨 👉No DLTs 👉42.1% pCR 👉pCR assoc with TMB, E2F activity 👉Global⬆️T-cell infiltration 👉pCR assoc with induction of TLS nature.com/articles/s4159…

🚨Out now Nature Medicine🚨 Final results from #CORE2 combining IVe Creto+Nivo in cis-ineligible MIBC pts nature.com/articles/s4159… No DLTs pCR = 42.1% pCR assoc with baseline free E2F activity, TMB Increased T cell infiltration Formation of TLS assoc with pCR Moffitt Cancer Center

Clinical research is integral to advancing treatment options and improving outcomes for patients. This past year, Mark Tyson is THE top provider in Arizona for enrollment in clinical trials, with genitourinary disease representing over 40% of total accruals!

Today, we announced topline data from BOND-003 Cohort P and first results from CORE-008 Cohort A which demonstrated promising efficacy, safety and tolerability. These data will be presented later today as Late-Breaking Abstracts at the Society of Urologic Oncology (SUO) 26th